Numerous studies have found that anti‐PD1 immunotherapy could be enhanced in patients with high PD‐L1 expression in the tumor microenvironment in certain malignancies, including HNSCC.27, 28. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.